DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)

South Korea · Delayed Price · Currency is KRW

19,740

-190 (-0.95%)

Sep 9, 2026, 3:30 PM KST

Market Cap	890.49B +17.1%
Revenue (ttm)	979.60B +12.7%
Net Income	76.30B +26.9%
EPS	1,697.71 +26.3%
Shares Out	45.11M
PE Ratio	11.63
Forward PE	9.73
Dividend	200.00 (0.92%)
Ex-Dividend Date	Dec 29, 2025

Volume	n/a
Open	19,740
Previous Close	19,930
Day's Range	19,740 - 19,740
52-Week Range	16,260 - 31,250
Beta	0.01
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About DongKook Pharmaceutical

DongKook Pharmaceutical Co., Ltd. produces and sells pharmaceutical products in South Korea and internationally. The company offers non-prescription and prescription drugs, quasi drugs, medical devices, active pharmaceutical ingredients, cosmetics, and other products. Its pipeline includes DKF-MB601, used to treat Hepatitis B; DKF-MB501, to treat obesity; DKM-412 and DKM-420 to treat osteoarthritis; DKF-313, indicated for benign prostatic hyperplasia; DKF-447, to treat diabetes; DKB-123, used for wound healing, tissue repair; and DKM-428, used ... [Read more]

Industry Medical - Pharmaceuticals

Sector Healthcare

Founded 1968

Employees 1,285

Stock Exchange KOSDAQ

Ticker Symbol 086450

Full Company Profile

Financial Performance

In 2025, DongKook Pharmaceutical's revenue was 926.88 billion, an increase of 14.12% compared to the previous year's 812.17 billion. Earnings were 66.02 billion, an increase of 8.64%.

Financial Statements